Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency

被引:60
作者
Siddall, Hilary K.
Warrell, Clare E.
Yellon, Derek M. [1 ]
Mocanu, Mihaela M.
机构
[1] Univ Coll London Hosp, Hatter Cardiovasc Inst, London WC1E 6HX, England
关键词
preconditioning; myocardium; ischemia-reperfusion injury; PTEN; Akt;
D O I
10.1007/s00395-008-0735-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Activation of the PI3K/Akt pathway protects the heart from ischemia-reperfusion injury (IRI). The phosphatase PTEN is the main negative regulator of this pathway. We hypothesized that reduced PTEN levels could protect against IRI. Isolated perfused mouse hearts from PTEN+/- and their littermates PTEN+/+ (WT), were subjected to 35 min global ischemia and 30 min reperfusion, with and without 2, 4 or 6 cycles ischemic preconditioning (IPC). The end point was infarct size, expressed as a percentage of the myocardium at risk (I/R%). PTEN and Akt levels were determined using Western blot analysis. Unexpectedly, there were no significant differences in infarction between PTEN+/- and WT (42.1 +/- 5.0% Vs. 45.6 +/- 3.3%). However, the preconditioning threshold was significantly reduced in the PTEN+/- Vs. WT, with 4 cycles of IPC being sufficient to reduce I/R%, compared to 6 cycles in the WT (4 cycles IPC: 29.8. +/- 3.69% in PTEN+/- Vs. 45.5. +/- 5.08% in WT, P < 0.01). In addition, the ratio between the phospho/total Akt (Ser473 and Thr308) was slightly but significantly increased in the PTEN+/- indicating an upregulation of PI3K/Akt pathway. Interestingly, the levels of the other phosphatases that may negatively regulate the PI3K/Akt pathway (PP2A, SHIP2 and PHLPP) were not significantly different between littermates and PTEN+/-. In conclusion, PTEN haploinsufficiency alone does not induce cardioprotection in this model; however, it reduces the threshold of protection induced by IPC.
引用
收藏
页码:560 / 568
页数:9
相关论文
共 32 条
[1]   The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases [J].
Backers, K ;
Blero, D ;
Paternotte, N ;
Zhang, J ;
Erneux, C .
ADVANCES IN ENZYME REGULATION, VOL 43, 2003, 43 :15-28
[2]   Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS [J].
Bell, RM ;
Yellon, DM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (02) :185-193
[3]  
Bhamra GS, 2008, BASIC RES CARDIOL, V103, P274, DOI [10.1007/s00395-007-0691-y, 10.1007/s00395-008-0736-x]
[4]   Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro [J].
Bullard, AJ ;
Yellon, DM .
CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (05) :333-336
[5]   PTEN activity is modulated during ischemia and reperfusion - Involvement in the induction and decay of preconditioning [J].
Cai, ZQ ;
Semenza, GL .
CIRCULATION RESEARCH, 2005, 97 (12) :1351-1359
[6]   Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways [J].
Crackower, MA ;
Oudit, GY ;
Kozieradzki, I ;
Sarao, R ;
Sun, H ;
Sasaki, T ;
Hirsch, E ;
Suzuki, A ;
Shioi, T ;
Irie-Sasaki, J ;
Sah, R ;
Cheng, HYM ;
Rybin, VO ;
Lembo, G ;
Fratta, L ;
Oliveira-dos-Santos, AJ ;
Benovic, JL ;
Kahn, CR ;
Izumo, S ;
Steinberg, SF ;
Wymann, MP ;
Backx, PH ;
Penninger, JM .
CELL, 2002, 110 (06) :737-749
[7]   PHLPP: A phosphatase that directly dephosphorylates akt, promotes apoptosis, and suppresses tumor growth [J].
Gao, TY ;
Furnari, F ;
Newton, AC .
MOLECULAR CELL, 2005, 18 (01) :13-24
[8]   Ischemic preconditioning targets the reperfusion phase [J].
Hausenloy, Derek J. ;
Wynne, Abigail M. ;
Yellon, Derek M. .
BASIC RESEARCH IN CARDIOLOGY, 2007, 102 (05) :445-452
[9]   Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning [J].
Hausenloy, DJ ;
Mocanu, MA ;
Yellon, DM .
CARDIOVASCULAR RESEARCH, 2004, 63 (02) :305-312
[10]   New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway [J].
Hausenloy, DJ ;
Yellon, DM .
CARDIOVASCULAR RESEARCH, 2004, 61 (03) :448-460